◎ Sugi Atlas

Atlas / Drug / Asparaginase

Asparaginase

drug
On this page

Also known as ColaspaseE. coli asparaginaseE. coli l-asparaginaseElsparEscherichia coli l-asparaginaseKidrolaseL-asparaginaseL-asparagine amidohydrolaseNSC-109229Spectrila

Summary

Asparaginase (CHEMBL2108989) is an approved enzyme (ATC L01XX02); indicated across 24 conditions including neoplasm and acute lymphoblastic leukemia; with CIViC clinical evidence for 10 variant-indication associations (e.g. ASNS Amplification in ovarian cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Enzyme
  • ATC class: L01XX02
  • Indications: 24 conditions
  • Clinical trials: 119
  • Precision-oncology evidence (CIViC): 10 variant–indication associations

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2108989
NameAsparaginase
TypeEnzyme
Max phase4
ATCL01XX02

Also known as: Asparaginase, Colaspase, E. coli asparaginase, E. coli l-asparaginase, Elspar, Escherichia coli l-asparaginase, Kidrolase, L-asparaginase, L-asparagine amidohydrolase, NSC-109229, Spectrila, ASPARAGINASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

24 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
acute lymphoblastic leukemia4MONDO:0004967EFO:0000220
lymphoid leukemia4MONDO:0005402EFO:0004289
lymphoma3MONDO:0005062EFO:0000574
myelodysplastic syndrome3MONDO:0018881EFO:0000198
acute myeloid leukemia3MONDO:0018874EFO:0000222
leukemia3MONDO:0005059EFO:0000565
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
myeloid sarcoma3MONDO:0006861EFO:1001052
acute erythroid leukemia3MONDO:0017858EFO:0000218
acute monocytic leukemia3MONDO:0007896EFO:0000221
acute myelomonocytic leukemia M43MONDO:0018871EFO:0000223
acute megakaryoblastic leukemia3MONDO:0018872EFO:0003025
acute myeloblastic leukemia without maturation3MONDO:0005224EFO:0003027
myelodysplastic syndrome with single lineage dysplasia3MONDO:0005272EFO:0003802
myelodysplastic syndrome with excess blasts3MONDO:0019454EFO:0003811
chronic myelomonocytic leukemia3MONDO:0020311EFO:1001779
acute basophilic leukemia3MONDO:0019458EFO:0003029
B-cell acute lymphoblastic leukemia2MONDO:0004947EFO:0000094
T-cell acute lymphoblastic leukemia2MONDO:0004963EFO:0000209

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 119.

Phase distribution

PhaseTrials
PHASE342
PHASE239
PHASE414
Not specified14
PHASE1/PHASE24
PHASE2/PHASE33
PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00198978PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00198991PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
NCT00199004PHASE4COMPLETEDTrial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
NCT00199017PHASE4COMPLETEDGerman Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
NCT00199056PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
NCT00199069PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
NCT00494897PHASE4COMPLETEDPETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
NCT00526175PHASE4COMPLETEDLAL-BR/2001: Study Treatment to Low Risk ALL
NCT00526305PHASE4COMPLETEDLAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
NCT00526409PHASE4COMPLETEDLAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia
NCT01358253PHASE4COMPLETEDRituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
NCT02036489PHASE4COMPLETEDPethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
NCT02894645PHASE4UNKNOWNMalaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
NCT03071822PHASE4UNKNOWNCombination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas
NCT02101853PHASE3ACTIVE_NOT_RECRUITINGBlinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02521493PHASE3ACTIVE_NOT_RECRUITINGResponse-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
NCT03020030PHASE3ACTIVE_NOT_RECRUITINGTreatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
NCT03150693PHASE3RECRUITINGInotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
NCT00002499PHASE2/PHASE3UNKNOWNCombination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia
NCT00002514PHASE3COMPLETEDStem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission
NCT00002700PHASE3COMPLETEDChemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
NCT00002744PHASE3COMPLETEDCombination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00002798PHASE3COMPLETEDCombination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NCT00002812PHASE3COMPLETEDCombination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
NCT00003423PHASE3UNKNOWNCombination Chemotherapy in Treating Children With Non-Hodgkin’s Lymphoma
NCT00003436PHASE3COMPLETEDCombination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia
NCT00003437PHASE3UNKNOWNHormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
NCT00003593PHASE3COMPLETEDChemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
NCT00003650PHASE3COMPLETEDCombination Chemotherapy in Treating Children With Non-Hodgkin’s Lymphoma
NCT00003728PHASE3UNKNOWNCombination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin’s Lymphoma
NCT00004228PHASE3COMPLETEDCombination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
NCT00005603PHASE3COMPLETEDCombination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
NCT00015873PHASE3COMPLETEDComparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia
NCT00019409PHASE3WITHDRAWNRadiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia
NCT00022737PHASE3COMPLETEDCombination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
NCT00131027PHASE3UNKNOWNHigh-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)
NCT00136084PHASE3COMPLETEDTreatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
NCT00137111PHASE3COMPLETEDTherapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
NCT00165087PHASE3TERMINATEDTreatment of Childhood Acute Lymphoblastic Leukemia
NCT00165178PHASE3COMPLETEDTreatment of Acute Lymphoblastic Leukemia in Children

Clinical evidence (CIViC)

Variant × indication × effect (10 predictive associations from 10 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
ASNS AmplificationOvarian CancerResistanceAsparaginaseCIViC DEID953
KMT2E::ASNS FusionT-cell Lymphoblastic Leukemia/lymphomaResistanceAsparaginaseCIViC DEID5926
PRPS1 A190TB-lymphoblastic Leukemia/lymphomaResistanceCytarabine + Asparaginase + Methotrexate + DaunorubicinCIViC DEID7928
PRPS1 D183EB-lymphoblastic Leukemia/lymphomaResistanceAsparaginase + Methotrexate + Cytarabine + DaunorubicinCIViC DEID7927
PRPS1 K176NB-lymphoblastic Leukemia/lymphomaResistanceDaunorubicin + Cytarabine + Methotrexate + AsparaginaseCIViC DEID7926
PRPS1 L191FB-lymphoblastic Leukemia/lymphomaResistanceAsparaginase + Daunorubicin + MethotrexateCIViC DEID7923
PRPS1 N144SB-lymphoblastic Leukemia/lymphomaResistanceDaunorubicin + Methotrexate + AsparaginaseCIViC DEID7930
PRPS1 S103NB-lymphoblastic Leukemia/lymphomaResistanceMethotrexate + Asparaginase + Daunorubicin + CytarabineCIViC DEID7925
PRPS1 S103TB-lymphoblastic Leukemia/lymphomaResistanceMethotrexate + Asparaginase + Daunorubicin + CytarabineCIViC DEID7924
PRPS1 T303SB-lymphoblastic Leukemia/lymphomaResistanceAsparaginase + Daunorubicin + Cytarabine + MethotrexateCIViC DEID7929

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 15

This page pulls from 15 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem